This study raises questions about the possible associations between carbidopa as an anti-nausea medication in Parkinson’s disease and an increase in Parkinson’s disease death rate. 

Marty Hinz, MD, of NeuroResearch Clinics Inc., and colleagues, note that during the first 15 years of prescribing L-dopa, the only known effective treatment for Parkinson’s, a decreasing disease death rate was observed. Then, in 1976, 1 year after US Food and Drug Administration approved the original L-dopa/carbidopa combination drug, the Parkinson’s disease death rate started increasing and has continued for 38 years and counting.

READ FULL ARTICLE Curated publisher From Dovepress